Cancer pain
Conditions
Interventions
Morphine Extended Release Tablets Group:Morphine Extended Release Tablets
Hydromorphone sustained-release tablets group:Hydromorphone sustained-release tablets
Sponsors
Kunming Yan 'an Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. The subjects voluntarily sign the informed consent form for this trial; 2. Patients diagnosed with malignant tumors by organization or pathology; 3. Age range of 18-80 years old, clear consciousness, regardless of gender; x; 4. Persistent cancer pain with NRS score >= 4 in the past 24 hours; 5. Patients who have not received radiation therapy within 7 days prior to randomization and trial; 6. ECOG-PS <= 3 points.
Exclusion criteria
Exclusion criteria: 1. The patient is diagnosed with non cancerous pain or unexplained pain; 2. Patients with paralytic intestinal obstruction; 3) Abnormal and clinically significant laboratory results, such as creatinine >= 2 times the upper limit of normal, ALT or AST >= 2.5 times the upper limit of normal (in patients with liver metastases or primary liver cancer >= 5 times the upper limit of normal), or Child C liver function; 4. Cognitive impairment; 5. Patients who are allergic to anesthetic drugs; 6. Pregnant or lactating patients; 7. Participate in drug trials (including the investigational drug) within one month prior to the trial; 8. Diseases and conditions that other researchers consider ineligible for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with effective analgesia;Adverse reaction incidence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Satisfaction evaluation;Quality of Life ;Proportion of patients with significant pain relief;Daily medication dosage;Daily frequency of pain outbreaks; | — |
Countries
China
Contacts
Public ContactWanbao Ding
Kunming Yan 'an Hospital
Outcome results
None listed